Université de Fribourg

The patent buyout price for human papilloma virus (HPV) vaccine and the ratio of R&D costs to the patent value

Songane, Mario ; Grossmann, Volker

In: PLOS One, 2021, p. 1-22

Human papillomavirus (HPV) is responsible for almost all of the 570,000 new cases of cervical cancer and approximately 311,000 deaths per year. HPV vaccination is an integral component of the World Health Organization’s (WHO) global strategy to fight the disease. However, high vaccine prices enforced through patent protection are limiting vaccine expansion, particularly in low- and...

Université de Fribourg

The patent buyout price for Human Papilloma Virus (HPV) vaccine and the ratio of R&D costs to the patent value

Songane, Mario ; Grossmann, Volker

(Working Papers SES ; 510)

Human papillomavirus (HPV) is responsible for almost all of the 530,000 new cases of cervical cancer and approximately 266,000 deaths per year. HPV vaccination is an integral component of the World Health Organization’s global strategy to fight the disease. However, high vaccine prices enforced through patent protection are limiting vaccine expansion, particularly in low- and middle-income...

Université de Fribourg

Patenting government funded innovations as a strategy to increase budget for academic vaccine R&D

Songane, Mario

(Working Papers SES ; 509)

Vaccine development is a lengthy, expensive and risky venture, with the research and development (R&D) process costing billions of dollars. The pre-clinical stage of vaccine R&D is largely performed by academic research institutions, then continued by the pharmaceutical industry though licensing agreements, taking the most promising candidates to the clinical testing stage. Governments play a...